Product information

From Health Canada

The product monograph is developed by a drug sponsor according to guidelines published by Health Canada that provide direction on the content and format. The veterinary labelling is developed by the drug sponsor according to the Food and Drug Regulations. While Health Canada reviews the product monograph or the veterinary labelling as part of the drug review process, it remains the responsibility of the drug sponsor to ensure that the product monograph or the veterinary labelling is complete and accurate.

Current status:

Cancelled Post Market

Current status date:

2020-09-25

Original market date: See footnote 1

2020-06-09

Lot number: See footnote 2

C995787J

Expiry date: See footnote 2

2020-10-22

Product name:

LARTRUVO

Description:

SINGLE-USE VIAL

Help on accessing alternative formats, such as Portable Document Format (PDF), Microsoft Word and PowerPoint (PPT) files, can be obtained in the alternate format help section.

DIN:

02480271

Product Monograph/Veterinary Labelling:

Date: 2018-08-22 Product monograph/Veterinary Labelling (PDF version ~ 175K)

Company:

ELI LILLY CANADA INC
SUITE 900 Exchange Tower, 130 King Street West
Toronto
Ontario
Canada M5X 1B1

Class:

Human

Dosage form(s):

Solution

Route(s) of administration:

Intravenous

Number of active ingredient(s):

1

Schedule(s):

Prescription ,  Schedule D

 

American Hospital Formulary Service (AHFS): See footnote 3

10:00.00 

Anatomical Therapeutic Chemical (ATC): See footnote 4

L01FX10 OLARATUMAB

Active ingredient group (AIG) number:See footnote5

0159610001

List of active ingredient(s)
Active ingredient(s) Strength
OLARATUMAB 190 MG / 19 ML
Version 4.0.2
Date modified: